THERAPY DOSSIER · th-fdb80aaca272

MASM ((6aS,10S,11aR,11bR,11cS)-10-methylaminododecahydro-3a,7a-diaza-benzo(de)anthracene-8-thione), a matrine derivative

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31357205 ↗2019Reported benefit

The Matrine Derivate MASM Inhibits Recruitment of Gr1hi Monocyte and Alleviates Liver Injury.

MouseChemical/toxinC57BL/6Male

Model: Acute and chronic liver injury induced by intraperitoneal carbon tetrachloride (CCl4) injection

MASM markedly reduced CCl4-induced acute liver injury and fibrosis on biochemical and histological assessment. The benefit was associated with lower Gr1hi monocyte infiltration into the liver and with reduced hepatic MCP-1 production and chemotactic activity.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…